Genetic Testing – Ayass BioScience, LLC

Genetic Testing – Ayass BioScience, LLC

Ayass BioScience, LLC – Contact Information

8501 Wade Blvd. Bldg 9, Frisco, TX 750934

Phone: 972-668-6005

Fax: 972-668-6720

Genetic Testing

Colon Cancer

By | April 10th, 2019|Genetic Testing|

March was National Colorectal Cancer Awareness month. Did you know that colorectal cancer is the second highest cause of cancer-related deaths in men and women, yet is one of the [...]

Prenatal Testing

By | March 2nd, 2017|Genetic Testing, Next Generation Sequencing|

Genetic Testing of Fetal Cell Free DNA - No Risk to Pregnancy (in Contrast with Amniocentesis) Fetal Cell Free DNA is present in subtle amounts in the bloodstream from as [...]

Ultra Sensitive Test for Circulating Tumor DNA At Ayass Bioscience!

By | January 19th, 2017|Circulating Tumor DNA, Genetic Testing, Research|

Detection Of Cancer at Early Stages! MUTATION DETECTION AT LOWER ALLELIC FRIEQUENCY! At Ayass BioScience we use an ultrasensitive method for detecting circulating tumor DNA. We can detect cancer with [...]

Liquid Biopsies – High Sensitivity Cancer Detection

By | January 16th, 2017|Circulating Tumor DNA, Genetic Testing, Next Generation Sequencing, Research|

SCREENING AND EARLY CANCER DETECTION • REAL TIME MONITORING OF CANCER THERAPY Dying cancer cells shed very small amount of DNA into blood. Gene-sequencing machines decode millions of short fragments [...]

Mitochondrial DNA (mtDNA) Mutation and Myopathy

By | January 10th, 2017|Genetic Testing, mtDNA, Next Generation Sequencing|

The Mitochondrial genome is extremely small when compared to the nuclear genome, and mitochondrial DNA (mtDNA) mutations are complex and difficult to trace, but they play an important role in [...]

Mass Spectrometry – Proteomics – Metabolomics – for Disease – Specific Biomarkers

By | December 22nd, 2016|Genetic Testing, Mass Spectrometry, Next Generation Sequencing, Research|

The Proteomics studies that corroborate Metabolomics findings are the next generation of laboratory testing using the Mass Spectrometry, a key technology for targeted protein and metabolite identification and quantification. This assay [...]

Solid Tumor NGS DNA Testing!

By | December 16th, 2016|Genetic Testing, Next Generation Sequencing, Solid Tumor|

At Ayass BioScience, we use high-throughput Next Generation Sequencing technology to sequence cancer patients' solid tumor DNA (Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Cervical cancer). Targeted sequencing of tumor DNA across our [...]

Your DNA Doesn’t Tell You the Whole Story

By | December 12th, 2016|Genetic Testing, Next Generation Sequencing|

We inherit DNA from our parents - but it only part of equation. Epigenetics is alteration in gene expression rather then the genetic code that affects genetics. DNA methylation, histone [...]

ctDNA Detection – CLIA Compliant Lab Developed Test!

By | December 8th, 2016|Circulating Tumor DNA, Genetic Testing, Next Generation Sequencing|

Ayass BioScience Circulating Tumor DNA (ctDNA) Assay is CLIA Compliant Lab Developed Test for Clinical Practice. Ayass BioScience ctDNA detects low levels of circulating tumor DNA (ctDNA) in the blood stream [...]

Next Generation Sequencing of Solid Tumor DNA

By | November 8th, 2016|Breast Cancer, Genetic Testing, Next Generation Sequencing, Solid Tumor|

Precision medicine is personalized medical care based on the genetic profiles of patients. At Ayass BioScience, we use high-throughput Next Generation Sequencing technologies to sequence cancer patients' solid tumor DNA. [...]

Leukemia Genetic Testing

By | November 7th, 2016|Circulating Tumor DNA, Genetic Testing, Next Generation Sequencing|

Leukemia is a cancer of blood forming tissues, such as bone marrow. A quick comprehensive genetic test can be used to supplement common detection methods of leukemia, and assist in [...]

BRCA1 and BRCA2 (BReast CAncer) are the best-known genes linked to breast cancer

By | November 3rd, 2016|Breast Cancer, Circulating Tumor DNA, Genetic Testing|

People who have a BRCA's mutation have much higher-than-average risk of developing breast cancer in both genders and ovarian cancer in women. With a blood test at Ayass BioScience, we [...]